Best printers for Home

Best Mixer Grinder

Best wired Earphones

Best 43 Inch TV in India

Best Wi Fi Routers

Best Home Theatre in India

Smart Watch under 5000

Best Laptops for Education

Best Laptop for Students

<ul><li>Airline stocks are enjoying a "full force" rebound in investor interest, <a href="https://markets.businessinsider.com/stocks/bac-stock">Bank of America</a> said Monday, but only certain firms are best positioned to weather weakened travel demand through the year.</li><li>Analyst Emma Young upgraded <a href="https://markets.businessinsider.com/stocks/alk-stock">Alaska Air</a> to "buy," saying the firm will increase its net debt in 2020 by only 8% compared to an average 40% increase among passenger airlines.</li><li> "Balance sheets and capital structures still matter, and we continue to favor airlines with more conservative balance sheets," she said.</li><li>Alaska stock surged as much as 11.8% to intraday highs, outperforming peer firms.</li><li><a href="https://markets.businessinsider.com/stocks/alk-stock">Watch Alaska Air trade live here</a>.</li></ul>The "recovery trade is in full force" for airline stocks and certain firms are emerging as investors' best bets, <a href="https://markets.businessinsider.com/stocks/bac-stock">Bank of America</a> said Monday.Analyst Emma Young upgraded <a href="https://markets.businessinsider.com/stocks/alk-stock">Alaska Air</a> shares to "buy" and lifted its price target to $53 from $36, implying a 24% gain from Friday's close. Alaska and <a href="https://markets.businessinsider.com/stocks/luv-stock">Southwest Airlines</a> are well-positioned for the industry's revival from travel lockdowns due to their strong balance sheets and efficient capital structures, she wrote. The firm also upgraded <a href="https://markets.businessinsider.com/stocks/jblu-stock">JetBlue</a> to "neutral" on hopes of recovering leisure-travel demand.<keyword id="6374849" type="UNKNOWN" weightage="60" keywordseo="bank-of-america">Bank of America</keyword> sees airlines recovering from their early-2020 slump to a 55% revenue decline from 90%. Rebounding leisure travel will certainly aid the sector, but its "true catalyst" for returning to past health will be the return of corporate demand, Young wrote. Until then, expect a heavier weighting of leisure interest to stifle revenues and lead firms with strong cash flow to outperform, she added.Read more: <a href="https://www.businessinsider.com/bearish-stock-market-economic-outlook-bubble-sage-legend-jeremy-grantham-2020-6">Jeremy Grantham, the legendary investor who called the past 3 bubbles, says investors should be nervous about recent market moves — and warns of 'deep economic wounds' regardless of a vaccine</a>"While the recovery is taking bankruptcy risk off the table, balance sheets and capital structures still matter, and we continue to favor airlines with more conservative balance sheets," the analyst said.<keyword id="3310464" type="COMPANY" weightage="60" keywordseo="Alaska-Air">Alaska Air</keyword> soared as much as 11.8% on the news but sits 30% lower year-to-date. The company broadly outperformed other airlines in Monday's session.The bank expects Southwest and Alaska to have the smallest growth in net debt by the end of 2020. Alaska will add only 8% to its total debt over the year compared to a 40% average increase among peers, Young projected.The industry's recovery could accelerate if a coronavirus vaccine becomes widely available, she added. The sector is anticipating a multi-year recovery before hitting 2019 demand, but a faster-than-expected treatment rollout would boost consumer comfort in traveling.Alaska joins Southwest and <a href="https://markets.businessinsider.com/stocks/algt-stock">Allegiant</a> as the only airlines with "buy" ratings from Bank of America. JetBlue, <a href="https://markets.businessinsider.com/stocks/dal-stock">Delta</a>, and <a href="https://markets.businessinsider.com/stocks/ual-stock">United Continental</a> hold "neutral" ratings, and the firm rates <a href="https://markets.businessinsider.com/stocks/aal-stock">American</a>, <a href="https://markets.businessinsider.com/stocks/save-stock">Spirit</a>, and <a href="https://markets.businessinsider.com/stocks/ha-stock">Hawaiian Airlines</a> "underperform."Now read more <keyword id="31671" type="CITY" weightage="100" keywordseo="markets">markets</keyword> coverage from Markets Insider and Business Insider:<a href="https://markets.businessinsider.com/news/stocks/jobs-report-unemployment-economy-bounce-stock-market-record-ed-yardeni-2020-6-1029288925">May's surprising jobs report sets stage for V-shaped recovery and fresh market highs, Wall Street bull Ed Yardeni says</a><a href="https://www.businessinsider.com/stock-market-crash-new-bull-run-historical-checklist-not-met-2020-6"></a><a href="https://markets.businessinsider.com/news/stocks/nasdaq-surpasses-nyse-ipo-warner-music-zoominfo-stock-debuts-most-2020-6-1029289412">Nasdaq surpasses NYSE in IPO activity after triumphant start to June</a><a href="https://www.businessinsider.com/stock-market-crash-new-bull-run-historical-checklist-not-met-2020-6">Stocks have met none of the 8 conditions that confirmed every new bull market in the post-war era — and one investment chief warns a relapse into a bear market is coming</a><div type="image" title="ALK" height="717" width="1058" msid="76268470" hostid="261"></div>

Bank of America adds a new airline to its 'buy' list as investors flock to the thrashed sector

<div class="KonaFilter image-container display-table"><div><div class="image"></div></div></div><ul><li>US airline stocks plummeted Wednesday after the World Trade Organization approved <a href="https://markets.businessinsider.com/news/stocks/wto-airbus-ruling-open-door-for-trump-tariffs-on-europe-2019-10-1028571481">President Trump's $7.5 billion worth of proposed tariffs</a> on the European Union. The duties will affect airplane parts and luxury goods.</li><li>The approval is the largest in the WTO's 24-year history, and further escalates the trade conflict between the bloc and the US.</li><li><a href="https://markets.businessinsider.com/stocks/ual-stock">United Airlines</a> and <a href="https://markets.businessinsider.com/stocks/aal-stock">American Airlines</a> both fell roughly 6%. <a href="https://markets.businessinsider.com/stocks/jblu-stock">JetBlue</a> fared better than its peers, dropping about 2.8%.</li><li><a href="https://www.businessinsider.com/" target="_blank" rel="noopener">Visit the Business Insider homepage for more stories</a>.</li></ul>Major US airlines saw their stocks tumble Wednesday after President Trump <a href="https://markets.businessinsider.com/news/stocks/wto-airbus-ruling-open-door-for-trump-tariffs-on-europe-2019-10-1028571481">won approval from the World Trade Organization</a> for $7.5 billion worth of tariffs on EU-based airplane parts and luxury goods.The approval is the largest in the WTO's 24-year history, nearly doubling the previous record from 2002. The tariffs affect the decades-long conflict between US-based Boeing and EU-based Airbus, with both companies accused of illegally using government funds to compete with the other.Here are the major US airlines hit by the announcement and how much they've fallen as of 1:30 p.m. ET:<ul><li>Alaska Air Group (<a href="https://markets.businessinsider.com/stocks/alk-stock">ALK</a>): down 4.6%</li><li>American Airlines (<a href="https://markets.businessinsider.com/stocks/aal-stock">AAL</a>): down 5%</li><li>Delta Air Lines (<a href="https://markets.businessinsider.com/stocks/dal-stock">DAL</a>): down 6.1%</li><li>JetBlue Airways (<a href="https://markets.businessinsider.com/stocks/jblu-stock">JBLU</a>): down 2.9%</li><li>Southwest Airlines (<a href="https://markets.businessinsider.com/stocks/luv-stock">LUV</a>): down 3.2%</li><li>Spirit Airlines (<a href="https://markets.businessinsider.com/stocks/save-stock">SAVE</a>): down 4.4%</li><li>United Airlines (<a href="https://markets.businessinsider.com/stocks/ual-stock">UAL</a>): down 5.7%</li></ul>Read more: <a href="https://markets.businessinsider.com/news/stocks/ism-factory-manufacturing-data-unexpectedly-contracts-hits-10-year-low-2019-10-1028567885">US factory activity unexpectedly hits 10-year low as Trump's trade war persists</a><a href="https://markets.businessinsider.com/stocks/ba-stock">Boeing</a> fell as much as 2.9% on the news, and <a href="https://markets.businessinsider.com/stocks/airbus-stock?utm_source=markets&amp;utm_medium=ingest">Airbus</a> dropped as much as 2.5%.The tariff announcement furthers Trump's trade conflict with the EU. The President already issued <a href="https://www.businessinsider.com/trump-tariffs-taxes-on-imports-of-steel-aluminum-could-be-trade-war-2018-3">a 25% duty on steel</a> from the bloc in March 2018, and is threatening <a href="https://markets.businessinsider.com/news/stocks/trump-delays-car-tariffs-for-six-months-2019-5-1028210961?utm_source=markets&amp;utm_medium=ingest">billions of dollars worth of tariffs on European cars</a>.The WTO ruling also permits tariffs on luxury goods from the EU including linen, cheese and swordfish. The organization is scheduled to rule on proposed tariffs from the EU early next year.Now read more markets coverage from Markets Insider and Business Insider:<a href="https://markets.businessinsider.com/news/stocks/johnson-and-johnson-stock-price-jumps-on-opioid-lawsuit-settlement-2019-10-1028571718">Johnson &amp; Johnson climbs after settling two opioid epidemic lawsuits, allowing it to avoid an upcoming federal trial</a><a href="https://markets.businessinsider.com/news/stocks/elizabeth-warren-presidency-impact-on-market-sectors-industries-at-risk-2019-10-1028571622">Wall Street is starting to take the possibility of an Elizabeth Warren presidency seriously - and strategists warn a victory could crush certain parts of the market</a><a href="https://www.businessinsider.com/benchmark-bill-gurley-valuations-are-causing-disappointing-tech-ipos-uber-2019-9">Uber and WeWork are being thrashed for pretending to be tech companies. But the VC whose firm bet big on both startups says that argument is all wrong.</a>

US airline stocks plummet after Trump wins WTO approval for tariffs on aircraft parts

<div class="KonaFilter image-container display-table"><div><div class="image on-image"><a href="https://www.shutterstock.com/image-photo/denver-circa-january-2016-southwest-airlines-365780282?src=SL5_AdpUb67abznFK3RslA-1-7">robert cicchetti/shutterstock</a></div></div></div><ul class="summary-list"><li><a href="https://www.businessinsider.com/category/southwest-airlines" target="_blank" rel="noopener">Southwest Airlines</a> on Wednesday blasted its mechanics union for hundreds of cancellations. </li><li>The union hit back, accusing the carrier of scapegoating.</li><li>Also on Wednesday, Southwest said the impact from the government shutdown could be triple what it previously warned.</li><li>Goldman Sachs downgraded the stock to sell on Tuesday, citing margin pressures from the launch of Hawaii flights. </li><li><a href="https://markets.businessinsider.com/stocks/luv-stock">Shares sank as much as 4% in early trading Wednesday. Follow trading in real-time here. </a></li></ul>It's not been a good week for <a href="https://www.businessinsider.com/category/southwest-airlines">Southwest Airlines.</a>The carrier on Wednesday blasted a mechanics union for hundreds of cancellations in recent days, a level it's calling unprecedented."On Feb. 12, just days after our last negotiations session with AMFA, we experienced an unprecedented number of out-of-service aircraft in four specific maintenance locations despite no change in our maintenance programs, no changes in leadership, and no changes in our policies and procedures," <a href="https://www.swamedia.com/releases/release-bc94d941a090ea44998912da1f90da5a-statement-from-southwest-airlines-chief-operating-officer-mike-van-de-ven">chief operations officer Mike Van de Ven said in a statement.</a>"We are committed to operating a safe fleet, and every report is investigated, which is why we issued a notice to require an "all hands" response to get out-of-service aircraft back into the fleet serving our Customers."This week alone, Southwest has canceled more than 600 flights, and delayed over 1000 others, <a href="https://flightaware.com/live/fleet/SWA/cancelled">according to FlightAware</a>. It blamed those interruptions on a number of planes out of service that was more than double the usual 20. Last week, it declared an <a href="https://www.usatoday.com/story/travel/flights/2019/02/15/southwest-airlines-aircraft-grounded-operations-emergency-mechanics-aircraft/2886285002/">operations "emergency" </a>The mechanics union hit back, accusing the airline of using it as a scapegoat for other issues."For Southwest's leadership to connect the airline's self-declared "operational emergency" to collective bargaining negotiations is simply an attempt to divert attention away from the airline's safety issues," <a href="http://www.amfanational.org/?zone=/unionactive/view_page.cfm&amp;page=Southwest20Airlines">the 2,700-member organization said in a statement.</a>Shares of Southwest sank more than 4% in trading Wednesday morning, as a revenue guide-down for the first quarter of 2019 and a Wall Street downgrade also weighed on investors' minds.Read more: <a href="https://www.businessinsider.com/how-assigned-seats-on-southwest-airlines-could-work-wall-street-analyst-2019-2" data-analytics-position="1">Assigned seats on Southwest? Here's how a major change would set the company apart from other airlines</a><a href="https://www.sec.gov/Archives/edgar/data/92380/000009238019000024/coverpage02-20x19.htm">In a regulatory filing Wednesday morning,</a> the airline said the government shutdown would have more of an impact than the previously disclosed $10 to 15 million. It now expects a negative revenue impact of $60 million due to "softness in passenger demand and bookings as a result of the government shutdown."Separately, a downgrade from Goldman Sachs related to its Hawaii launch was also adding to the airline's headache. Analyst Catherine O'Brien cut her rating to sell for the stock, saying the new routes could shrink Southwest's pretax margins by 60 basis points."We continue to be positive on LUV's long-term thesis, but we prefer ALK at this time," she said in a note to clients Tuesday evening. <div class="margin-top"> <h3>NOW WATCH: <a href="https://www.businessinsider.com/tesla-roadster-what-fans-should-know-electric-vehicles-cars-2019-2">Everything you need to know about Tesla's new Roadster</a></h3> <div> </div> </div>

Southwest has blamed an 'unprecedented' number of canceled flights on a mechanics union - and the stock is tanking

<div class="KonaFilter image-container display-table float_right"><div><div class="image on-image"></div></div></div>Shares of JetBlue Airways (<a href="http://markets.businessinsider.com/stock/JBLU-Quote">JBLU</a>) are down almost 12% so far this year and Morgan Stanley says it's still not the time to buy. After a big post-election run, airline stocks have cooled since the beginning of March. An unexpected drop in demand and higher year over year fuel prices have caused many airlines to <a href="http://markets.businessinsider.com/news/stocks/delta-warns-on-margin-pressures-2017-3-1001807696">issue guidance revisions</a> to the downside. The US Global Jets ETF (<a href="http://markets.businessinsider.com/etfs/US-Global-Jets-ETF">JETS</a>) that tracks major airlines is down about 5% over the last two weeks.In a note circulated on March 15, the investment bank agreed with surveyed investors, 63% of whom found the company "less attractive than consensus" based on valuation. Morgan Stanley predicts a Revenue Per Available Seat Mile (RASM) shortfall for 2017 and 2018 plus additional earnings pressure from next year's pilot contract. The result: the bank estimates EPS of $1.59 to $1.60 roughly 12% to 20% below consensus. If Morgan Stanley is right, JetBlue would still trade at about a 12.5x multiple, full value for an airline stock.Over the long-term, the brokerage house does see opportunity in JetBlue with coming improvements such as fare options, mint class, cabin restyling, and credit card perks.However, in the short-term, margins are suppressed at 14% compared to peers like Alaska Air (<a href="http://markets.businessinsider.com/stock/ALK-Quote">ALK</a>) and Southwest (<a href="http://markets.businessinsider.com/stock/LUV-Quote">LUV</a>) which are at 21% and 18%, respectively. Morgan Stanley remains unenthusiastically equal-weight on JBLU with a price target of $21, the stock closed Tuesday's session at $19.63 a share. Although the stock is currently below its target price, Morgan Stanley is not recommending accumulating shares at this time. <div class="KonaFilter image-container display-table"><div><div class="image on-image"></div></div></div> <div class="margin-top"> <h3>NOW WATCH: <a href="http://www.businessinsider.com/7-mega-billionaires-who-made-a-fortune-last-year-2017-3">7 mega-billionaires who made a fortune last year</a></h3> <div> <div> <div class="ooyala-video-player" data-video-autoplay="false" data-video-id="txZTM5YTE64gA4GFRYvPGavZ6kzc9laH" data-player-variable="ooyalapopvideo" id="ooyalaplayer_popvideo" style="width:1280px;height:720px"></div> </div> </div> </div>

MORGAN STANLEY: It's too early to buy JetBlue

<div class="KonaFilter image-container display-table float_right"><div><div class="image">Bill Pugliano/Getty Images</div></div></div>Here's a big, juicy M&amp;A story to get the market excited on a Monday morning.
Pharmaceutical giant Pfizer has said in a new press release that it has approached UK pharmacuetical maker AstraZeneca about a $100 billion takeover offer, but that AstraZeneca so far has shown no interest in doing a deal.
Pfizer made the announcement in a press release, indicating that earlier discussions had ended in mid-January, and that Pfizer tried to engage in new discussions on April 26, but to no avail.
Shares of AstraZeneca are surging 15% this morning.
In the announcement, which you can read below, Pfizer says the deal would have benefits in terms of distribution brand, and improving the company's product portfolio.
Pfizer will hold a conference call later this morning to discuss the proposal.
--------------------------------------------------------------
Pfizer Inc. confirms that it previously submitted a preliminary, non-binding indication of interest to the board of directors of AstraZeneca in January 2014 regarding a possible merger transaction. After limited high-level discussions, AstraZeneca declined to pursue negotiations. The discussions were discontinued on 14 January 2014 and Pfizer then ceased to consider a possible transaction. In light of recent market developments, Pfizer contacted AstraZeneca on 26 April 2014 seeking to renew discussions in order to develop a proposal that could be recommended by both companies to their shareholders. AstraZeneca again declined to engage. Pfizer is currently considering its options with respect to AstraZeneca.
Pfizer's previous proposal made to the board of AstraZeneca on 5 January 2014 included a combination of cash and shares in the combined entity which represented an indicative value of £46.61 ($76.62)1 per AstraZeneca share and a substantial premium of approximately 30% to AstraZeneca's closing share price of £35.86 on 3 January 2014.
As in its previous proposal, Pfizer is considering a possible transaction in which AstraZeneca shareholders would receive a significant premium for their AstraZeneca shares, to be paid in a combination of cash and shares in the combined entity. Pfizer believes that a transaction, if proposed and consummated, would offer AstraZeneca shareholders a highly compelling opportunity to realise a significant premium to the undisturbed AstraZeneca share price as of 17 April 2014, which includes a substantial cash payment. AstraZeneca shareholders would become significant shareholders in the combined company and participate in significant value creation opportunities, including benefiting from the potential growth opportunities and operational and financial synergies that the combination of two complementary global pharmaceutical companies would be expected to generate. Pfizer is confident a combination is capable of being consummated. The transaction, if consummated, is expected to result in the combination of the two companies under a new U.K.-incorporated holding company. As a global corporation, Pfizer would expect the combined company to have management in both the United States and the United Kingdom, and to maintain head offices in New York and list its shares on the New York Stock Exchange.
The making of any firm offer by Pfizer would be subject to the following pre-conditions (which may be waived in whole or in part by Pfizer):
<ul id="yui_3_9_1_1_1398672260981_1523">
<li id="yui_3_9_1_1_1398672260981_1522" class="bwlistitemmargb">satisfactory completion of a customary due diligence review by Pfizer;</li>
<li class="bwlistitemmargb">unanimous recommendation by the directors of AstraZeneca to vote in favour of the combination; and</li>
<li class="bwlistitemmargb">the directors of AstraZeneca giving irrevocable undertakings to accept any offer in respect of their AstraZeneca shares.</li>
</ul>
Commenting on the possible transaction, Ian Read, Chairman and CEO of Pfizer, said:
"We have great respect for AstraZeneca and its proud heritage as an innovation-driven biopharmaceutical business with a rich science-based foundation in both the United Kingdom and Sweden. In addition, the United Kingdom has created attractive incentives for companies to manufacture products and maintain and protect intellectual property, and we have seen that capital and jobs have followed these types of incentives.
"We believe patients all over the globe would benefit from our shared commitment to R&amp;D, which is critical to the future success of the pharmaceutical industry, in the form of potential new therapies that help to fight some of the world's most feared diseases, such as cancer.
"The combination of Pfizer and AstraZeneca could further enhance the ability to create value for shareholders of both companies and bring an expanded portfolio of important treatments to patients. A potential combination with AstraZeneca aligns with Pfizer's current structure and fully supports its existing strategy to build world-class businesses. The combination would complement our two innovative businesses and our Global Established Pharmaceutical business, allowing us to maintain the flexibility for the potential future separation of our businesses whilst at the same time broadening our pipeline breadth and potential new product launches over coming years. We believe that a transaction would further strengthen our ability to generate strong and consistent cash flow, targeted for both investment in our business and return to shareholders, while at the same time offering an efficient operating structure and the anticipated realization of attractive synergies.
"As always, we continue to focus on value creation and will be disciplined in our approach to capital deployment. Pfizer has a proven track record of successful acquisitions and, if a transaction were consummated, would use its extensive integration experience to support a successful combination of the businesses and focus on delivering value to shareholders."
Pfizer believes the strategic, business and financial rationale for a transaction is compelling. Pfizer believes the possible combination would create a highly complementary mapping of products, pipeline and operating assets to Pfizer's new operating structure, providing additional critical mass to all business segments and strong cash flow through:
<ul id="yui_3_9_1_1_1398672260981_1596">
<li class="bwlistitemmargb">an industry-leading combined portfolio of molecularly targeted medicines for lung cancer, including novel agents for ALK, EGFR and KRas subtypes;</li>
<li class="bwlistitemmargb">strengthened presence in breast cancer, including the ongoing phase 3 trial which combines palbociclib with Faslodex for women with recurrent, metastatic hormone-sensitive disease;</li>
<li class="bwlistitemmargb">opportunities for greater depth in immuno-oncology, including the option to combine anti-PD-L1 with palbociclib, Xalkori or Inlyta for breast, lung and renal cancer respectively. Additionally, molecules targeting PD-L1, CTLA4 and 41BB offer attractive opportunities for combination immuno-oncology therapy in several cancer indications, including lung cancer and melanoma;</li>
<li class="bwlistitemmargb">a strong complementary portfolio of important cardiovascular medicines, such as Brilinta and Eliquis and promising development stage programs, such as bococizumab (PCSK9);</li>
<li class="bwlistitemmargb">a broad, innovative commercial offering of non-insulin anti-diabetic medicines that complements Pfizer's early-stage research initiatives and capabilities in diabetes;</li>
<li class="bwlistitemmargb">a Global Established Pharmaceutical business with integrated distribution capabilities, expanded reach to healthcare providers and a broad portfolio of market-leading products generating strong and consistent cash flow; and</li>
<li id="yui_3_9_1_1_1398672260981_1595" class="bwlistitemmargb">a strengthened global footprint and enhanced opportunities in developing markets.</li>
</ul>
The possible transaction is expected to be accretive to Pfizer's adjusted diluted earnings per share2 in the first full year following the combination3. In addition, Pfizer has a track record of realising operational synergies and delivering meaningful value accretion for shareholders in prior transactions of a similar type and scale. Pfizer believes that synergies would be achieved through the combination of the two companies' operations and that the combination would enable greater capital efficiency and a more efficient tax structure. In particular, the currently contemplated structure under a new U.K.-incorporated holding company would not subject AstraZeneca's non-U.S. profits to U.S. tax, which would be in the best interests of the combined company's shareholders.
The completion of a possible transaction is subject to the approval of Pfizer's shareholders and is expected to be a taxable event to Pfizer's shareholders.
Pfizer reserves the right to introduce other forms of consideration and/or vary the mix of consideration and waive in whole or in part any of the pre-conditions to making an offer.
Pfizer reserves the right to make an offer for AstraZeneca at any time for less than the equivalent of £46.61 ($76.62) for each AstraZeneca share:
(i) with the agreement or recommendation of the AstraZeneca board;
(ii) if a third party announces a firm intention to make an offer for AstraZeneca which, as at the date Pfizer announces a firm intention to make an offer for AstraZeneca, is valued at a lower price than the equivalent of £46.61 ($76.62) for each AstraZeneca share;
(iii) following the announcement by AstraZeneca of a whitewash transaction4 pursuant to the Code; or
(iv) in the event that any AstraZeneca dividend is declared, made or paid in excess of what is expected by the consensus analyst forecasted dividends of 53.6 pence5 per share due to be announced by AstraZeneca on 31 July 2014, a £ for £ adjustment reduction equal to the excess amount.
The deadline set by Rule 2.6(a) of the Code (the "Deadline") requires Pfizer either:
(i) to announce a firm intention to make an offer for AstraZeneca under Rule 2.7 of the Code; or
(ii) to announce that it does not intend to make an offer for AstraZeneca, in which case the announcement will be treated as a statement to which Rule 2.8 of the Code applies,
by not later than 5.00 pm on 26 May 2014, save where either:
(i) AstraZeneca and the Takeover Panel have consented to an extension of the Deadline; or
(ii) the Deadline does not apply, or ceases to apply, by virtue of Rule 2.6(b) (a firm intention to make an offer for AstraZeneca under Rule 2.7 of the Code being announced by an offeror (other than Pfizer) prior to the Deadline).
A copy of this announcement will be available on Pfizer's website at <a href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.pfizer.com&amp;esheet=50851997&amp;newsitemid=20140427005064&amp;lan=en-US&amp;anchor=www.pfizer.com&amp;index=1&amp;md5=3c960644e31ebbe36e13d4fe9d054246" data-rapid_p="8">www.pfizer.com</a>.
Pfizer will hold an analyst and investor call in respect of this announcement today at 8:30 a.m. EDT (1:30 p.m. BST). A live and recorded webcast will be available from <a href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.pfizer.com&amp;esheet=50851997&amp;newsitemid=20140427005064&amp;lan=en-US&amp;anchor=www.pfizer.com&amp;index=2&amp;md5=356e6c438ebab77444e3b68f9bb1ae8b" data-rapid_p="9">www.pfizer.com</a>.

You Searched For "alk stock" and got 5 results

Bank of America adds a new airline to its 'buy' list as investors flock to the thrashed sector

Ben Winck

US airline stocks plummet after Trump wins WTO approval for tariffs on aircraft parts

Ben Winck

Southwest has blamed an 'unprecedented' number of canceled flights on a mechanics union - and the stock is tanking

Graham Rapier

MORGAN STANLEY: It's too early to buy JetBlue

Greg Hoffman

Pfizer Confirms It Wants To Do A Blockbuster Takeover Of AstraZeneca

Joe Weisenthal

Popular Keywords

Buying Guides